ATOSSA THERAPEUTICS, INC. financial data

Symbol
ATOS on Nasdaq
Location
Seattle, WA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1028% % -33%
Debt-to-equity 10% % 56%
Return On Equity -49% % -52%
Return On Assets -45% % -47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 129,171,424 shares 2.7%
Common Stock, Shares, Outstanding 129,171,424 shares 3.1%
Entity Public Float $149,586,095 USD -6.2%
Common Stock, Value, Issued $23,488,000 USD 2.6%
Weighted Average Number of Shares Outstanding, Basic 129,171,424 shares 2.7%
Weighted Average Number of Shares Outstanding, Diluted 129,171,424 shares 2.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $18,433,000 USD 13%
General and Administrative Expense $14,423,000 USD 9.9%
Operating Income (Loss) $32,856,000 USD -11%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $30,180,000 USD -12%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $30,180,000 USD -12%
Earnings Per Share, Basic 0 USD/shares -4.5%
Earnings Per Share, Diluted 0 USD/shares -4.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $51,845,000 USD -31%
Assets, Current $55,678,000 USD -28%
Other Assets, Noncurrent $2,334,000 USD -1.4%
Assets $58,012,000 USD -27%
Accounts Payable, Current $3,536,000 USD 127%
Employee-related Liabilities, Current $1,125,000 USD 6%
Accrued Liabilities, Current $1,989,000 USD 17%
Liabilities, Current $8,225,000 USD 42%
Liabilities $8,225,000 USD 42%
Retained Earnings (Accumulated Deficit) $235,625,000 USD -15%
Stockholders' Equity Attributable to Parent $49,787,000 USD -32%
Liabilities and Equity $58,012,000 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,959,000 USD -27%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $9,000 USD -50%
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 129,171,424 shares 2.7%
Common Stock, Par or Stated Value Per Share 0.18 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,968,000 USD -33%
Deferred Tax Assets, Valuation Allowance $29,516,000 USD 20%
Deferred Tax Assets, Gross $29,563,000 USD 19%
Depreciation $4,000 USD -20%
Payments to Acquire Property, Plant, and Equipment $9,000 USD 50%
Deferred Tax Assets, Operating Loss Carryforwards $15,716,000 USD 18%
Preferred Stock, Shares Issued 577 shares -0.86%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $263,399,000 USD 2.2%
Preferred Stock, Shares Outstanding 577 shares -0.86%
Deferred Tax Assets, Net of Valuation Allowance $47,000 USD -50%
Share-based Payment Arrangement, Expense $2,917,000 USD 43%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%